~16 spots leftby Apr 2026

Antibiotics for Urinary Tract Infections After Bladder Surgery

Recruiting in Palo Alto (17 mi)
KA
Overseen byKhurshid A. Guru
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 4
Waitlist Available
Sponsor: Roswell Park Cancer Institute
No Placebo Group
Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial investigates whether a one-month course of preventative (prophylactic) antibiotics helps to reduce urinary tract infections after robot-assisted surgery to remove all of the bladder as well as nearby tissues and organs (radical cystectomy). Urinary tract infections are a common occurrence after robot-assisted radical cystectomy. Antibiotics such as trimethoprim-sulfamethoxazole or nitrofurantoin may prevent or control infections in patients with urinary tract infection and may help improve their response to radical cystectomy. Information gained from this study may help researchers to predict patient complications and identify better ways to manage these complications.

Research Team

KA

Khurshid A. Guru

Principal Investigator

Roswell Park Cancer Institute

Eligibility Criteria

This trial is for patients planning to undergo robot-assisted surgery to remove the bladder due to muscle-invasive or refractory non-muscle invasive bladder cancer. Participants must understand and consent to the study's nature. Excluded are those with myasthenia gravis, QT prolongation, severe kidney issues, pregnant/nursing women, and anyone who can't follow the protocol.

Inclusion Criteria

I choose to have a robot-assisted surgery for bladder removal and can consent.
Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
I am choosing to have a cystectomy for my bladder cancer.

Exclusion Criteria

I am a woman who had a fertility-preserving bladder surgery.
My kidney function is low, with a creatinine clearance under 30 mL/min.
I do not have a history of abnormal heart rhythms nor take medication that affects it.
See 5 more

Treatment Details

Interventions

  • Clindamycin (Antibiotic)
  • Diary (Other)
  • Ertapenem (Antibiotic)
  • Levofloxacin (Antibiotic)
  • Nitrofurantoin (Antibiotic)
  • Trimethoprim-Sulfamethoxazole (Antibiotic)
Trial OverviewThe trial tests if a one-month course of antibiotics like trimethoprim-sulfamethoxazole or nitrofurantoin after robot-assisted radical cystectomy reduces urinary tract infections. It aims to improve post-surgery outcomes and manage complications better.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Group I (trimethoprim-sulfamethoxazole, nitrofurantoin)Experimental Treatment6 Interventions
Patients receive ertapenem PO, levofloxacin PO, or clindamycin PO induction therapy per standard of care. At the time of full diet, patients receive trimethoprim-sulfamethoxazole PO daily or nitrofurantoin PO daily on days 1-30. Patients complete a drug diary for each day they receive the antibiotic.
Group II: Group II (standard of care)Active Control3 Interventions
Patients receive ertapenem PO, levofloxacin PO, or clindamycin PO induction therapy per standard of care.

Clindamycin is already approved in Canada, Japan for the following indications:

🇨🇦
Approved in Canada as Cleocin for:
  • Serious bacterial infections
  • Anaerobic bacterial infections
  • Streptococcal infections
  • Staphylococcal infections
  • Pneumococcal infections
🇯🇵
Approved in Japan as Clindamycin for:
  • Serious bacterial infections
  • Anaerobic bacterial infections
  • Streptococcal infections
  • Staphylococcal infections
  • Pneumococcal infections

Find a Clinic Near You

Who Is Running the Clinical Trial?

Roswell Park Cancer Institute

Lead Sponsor

Trials
427
Recruited
40,500+
Dr. Julia Faller profile image

Dr. Julia Faller

Roswell Park Cancer Institute

Chief Medical Officer since 2024

DO from an unspecified institution

Dr. Candace S. Johnson profile image

Dr. Candace S. Johnson

Roswell Park Cancer Institute

Chief Executive Officer since 2015

PhD in Immunology from The Ohio State University